ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Wednesday, 18 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Investor Presentation

Chandan Healthcare Investor Presentation: Key Takeaways

Q2 FY27 standalone revenue ₹57.94 Cr (+45%), EBITDA margin 37.26%, PAT ₹18.61 Cr including a ₹10.23 Cr one-time gain. Now pure-play diagnostics after pharmacy divestment.

Highlights
Revenue growthQ2 +45.04%, H1 +41.16% YoY standalone
MarginsQ2 EBITDA margin 37.26%, +241 bps YoY; H1 36.95%
Demand visibilityB2G long-tenure PPP contracts; Jeena Sikho run-rate above ₹1.50 Cr monthly

Growth

H1 revenue ₹106.61 Cr (+41.16%), EBITDA ₹40.31 Cr (+66.52%). Ex-exceptional H1 PAT ~₹15.14 Cr vs ₹7.11 Cr (~+113%).

Outlook

1,000 franchises by FY27-end (685 now), 3,000 in two years. ~₹10 Cr residual capex by Dec 2026.

Risks

Q2 PAT flattered by non-recurring ₹10.23 Cr gain. Assam and Haryana PPP sites pending handover. B2G mix capped at ~40%.

Source

Investor Presentation filed with NSE, NSE: CHANDAN. Summary written with AI assistance from the document.

Read the document ↗

Chandan Healthcare Ltd: key numbers

Share price
₹234.75
Market cap
₹603.4 Cr
Revenue (annual)
₹276.4 Cr
Net profit (annual)
₹27.06 Cr
P/E (TTM)
22.3×Sector 56.7×
Promoter holding
47.20%-2.41% QoQ
FII holding
0.00%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Chandan Healthcare Ltd

All →